Strategic decision-making in the pharmaceutical industry: A unified decision-making framework

被引:9
作者
Marques, Catarina M. [1 ,2 ]
Moniz, Samuel [3 ]
de Sousa, Jorge Pinho [1 ,2 ]
机构
[1] Univ Porto, Fac Engn, Rua Dr Roberto Frias, Porto, Portugal
[2] INESC TEC, Rua Dr Roberto Frias, Porto, Portugal
[3] Univ Coimbra, Dept Engn Mecan, Coimbra, Portugal
关键词
Uncertainty; Strategic decisions; Process design; Capacity planning; Multi-Objective Integer Programming; Pharmaceutical industry; RESEARCH-AND-DEVELOPMENT; DEVELOPMENT PIPELINE MANAGEMENT; SIMULATION-OPTIMIZATION FRAMEWORK; MULTIPURPOSE BATCH PLANTS; PRODUCT DEVELOPMENT; DRUG DEVELOPMENT; MULTIOBJECTIVE OPTIMIZATION; SUCCESS RATES; SUPPLY CHAINS; UNCERTAINTY;
D O I
10.1016/j.compchemeng.2018.09.010
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The implementation of efficient strategic decisions such as process design and capacity investment under uncertainty, during the product development process, is critical for the pharmaceutical industry. However, to tackle these problems the widely used multi-stage/scenario-based optimization formulations are still ineffective, especially for the first-stage (here-and-now) solutions where uncertainty has not yet been revealed. This study extends the authors' previous work addressing the stochastic product-launch planning problem, by developing a new Multi-Objective Integer Programming model, embedded in a unified decision-making framework, to obtain the final design strategy that "maximizes" productivity while considering the decision-maker preferences. An approximation of the efficient Pareto-front is determined, and a subsequent Pareto solutions analysis is made to guide the decision process. The developed approach clearly identifies the process designs and production capacities that "maximize" productivity as well as the most promising solutions region for investment. Moreover, a good balance between investment and capacity allocation was achieved. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:171 / 189
页数:19
相关论文
共 54 条
[11]   LINEAR PROGRAMMING UNDER UNCERTAINTY [J].
Dantzig, George B. .
MANAGEMENT SCIENCE, 1955, 1 (3-4) :197-206
[12]   Clinical Approval Success Rates for Investigational Cancer Drugs [J].
DiMasi, J. A. ;
Reichert, J. M. ;
Feldman, L. ;
Malins, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) :329-335
[13]   Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs [J].
DiMasi, J. A. ;
Feldman, L. ;
Seckler, A. ;
Wilson, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :272-277
[14]   Innovation in the pharmaceutical industry: New estimates of R&D costs [J].
DiMasi, Joseph A. ;
Grabowski, Henry G. ;
Hansen, Ronald W. .
JOURNAL OF HEALTH ECONOMICS, 2016, 47 :20-33
[15]   Improving lead time of pharmaceutical production processes using Monte Carlo simulation [J].
Eberle, Lukas Gallus ;
Sugiyama, Hirokazu ;
Schmidt, Rainer .
COMPUTERS & CHEMICAL ENGINEERING, 2014, 68 :255-263
[16]  
EFPIA, 2016, PHARM IND FIG 2016
[17]   Planning models for parallel batch reactors with sequence-dependent changeovers [J].
Erdirik-Dogan, Muge ;
Grossmann, Ignacio E. .
AICHE JOURNAL, 2007, 53 (09) :2284-2300
[18]   Decision-support tool for assessing biomanufacturing strategies under uncertainty: Stainless steel versus disposable equipment for clinical trial material preparation [J].
Farid, SS ;
Washbrook, J ;
Titchener-Hooker, NJ .
BIOTECHNOLOGY PROGRESS, 2005, 21 (02) :486-497
[19]   Process R&D under the magnifying glass: Organization, business model, challenges, and scientific context [J].
Federsel, Hans-Jurgen .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (16) :5775-5794
[20]   Capacity planning under uncertainty for the pharmaceutical industry [J].
Gatica, G ;
Papageorgiou, LG ;
Shah, N .
CHEMICAL ENGINEERING RESEARCH & DESIGN, 2003, 81 (A6) :665-678